↑ 疾患リストへ ← 戻る

 130. 先天性無痛無汗症 [臨床試験数:1,薬物数:9(DrugBank:7),標的遺伝子数:4,標的パスウェイ数:6] 

Searched query = "Congenital insensitivity to pain with anhydrosis", "CIPA", "Hereditary sensory and autonomic neuropathy type IV", "HSAN4", "Hereditary sensory and autonomic neuropathy type V", "HSAN5"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03070470March 14, 201716 December 2017CiPA Phase 1 ECG Biomarker Validation StudyComprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)Drug-induced QT Prolongation;Pharmacokinetics;PharmacodynamicsDrug: Ranolazine;Drug: Verapamil;Drug: Lopinavir / Ritonavir;Drug: Chloroquine;Drug: Placebo;Drug: Dofetilide and DiltiazemFood and Drug Administration (FDA)Spaulding Clinical Research LLCNot recruiting18 Years50 YearsAll57Phase 1United States